Semaglutide Gets FDA Advisory Committee Backing
October 19th 2017Officials with Novo Nordisk have announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes.
Read More